Asio Capital LLC Has $3.11 Million Stake in Johnson & Johnson $JNJ

Asio Capital LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 11.5% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 20,357 shares of the company’s stock after selling 2,639 shares during the quarter. Asio Capital LLC’s holdings in Johnson & Johnson were worth $3,110,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Elios Financial Group Inc. boosted its holdings in shares of Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock valued at $746,000 after purchasing an additional 66 shares in the last quarter. Atlantic Family Wealth LLC lifted its position in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after buying an additional 67 shares during the last quarter. MBA Advisors LLC grew its position in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. raised its stake in Johnson & Johnson by 1.8% during the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock worth $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc lifted its holdings in shares of Johnson & Johnson by 1.5% in the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after acquiring an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In other news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the transaction, the executive vice president directly owned 178,013 shares of the company’s stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Price Performance

Shares of JNJ opened at $185.40 on Wednesday. The business has a 50-day moving average of $175.11 and a 200-day moving average of $162.34. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The company has a market capitalization of $446.51 billion, a price-to-earnings ratio of 19.83, a price-to-earnings-growth ratio of 2.31 and a beta of 0.40. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $185.99.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company’s revenue for the quarter was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th were issued a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the stock. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a “neutral” rating in a research report on Thursday, July 17th. Citigroup upped their price target on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, August 21st. Wall Street Zen raised Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Barclays upped their target price on Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a report on Thursday, July 17th. Finally, Erste Group Bank raised Johnson & Johnson from a “hold” rating to a “buy” rating in a research note on Wednesday, July 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have given a Hold rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average price target of $181.40.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.